Akt inhibitors: mechanism of action and implications for anticancer therapeutics

Jaikrit Bhutani, Asfandyar Sheikh1, Asfandyar Khan Niazi

  • 1Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan. asfandyarsheikh@gmail.com.

Insights

Protein kinase B (Akt/PKB) is crucial in cell processes and cancer. Understanding Akt signaling pathways is vital for developing new anticancer drugs and overcoming resistance.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Akt, also known as protein kinase B (PKB), is a key serine/threonine kinase.
  • It mediates critical cellular functions including glucose metabolism, apoptosis, cell differentiation, and transcription through the PI3K/Akt pathway.
  • Aberrant Akt signaling, particularly gene amplification of Akt1 and Akt2, is associated with various cancers like gastric, ovarian, pancreas, and breast tumors.

Purpose of the Study:

  • To highlight the significance of Akt signaling in biological processes and cancer.
  • To emphasize the need for a comprehensive understanding of Akt and its associated pathways (PI3K, PKB, mTOR) for therapeutic advancements.
  • To explore the potential of Akt inhibitors in cancer treatment strategies.

Main Methods:

  • Review of existing literature on Akt signaling pathways.
  • Analysis of the role of Akt gene amplification in different cancer types.
  • Discussion of the therapeutic implications of targeting the PI3K/Akt/mTOR pathway.

Main Results:

  • Akt plays a central role in fundamental cellular processes.
  • Akt1 and Akt2 gene amplifications are implicated in the development and progression of multiple human cancers.
  • Akt inhibitors show promise as monotherapy or in combination treatments for overcoming drug resistance.

Conclusions:

  • A thorough understanding of Akt and its signaling network is essential for novel drug development.
  • Targeting Akt signaling presents a promising strategy for improving anticancer therapy and managing drug resistance.
  • Further research into Akt pathways can lead to more effective cancer treatments.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

4.3K
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
58
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
9.2K